Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.95)
# 3,132
Out of 4,975 analysts
56
Total ratings
28.57%
Success rate
11.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GERN Geron | Reinstates: Sell | $1 | $1.40 | -28.57% | 4 | Jul 10, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $59 → $66 | $102.12 | -35.37% | 8 | Dec 5, 2024 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $32.21 | -31.70% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $7.66 | +95.82% | 2 | May 14, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $53 → $46 | $27.16 | +69.37% | 5 | May 13, 2024 | |
| ROIV Roivant Sciences | Maintains: Buy | $16 → $18 | $12.92 | +39.32% | 5 | Apr 3, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $3.78 | +243.92% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $35.99 | -22.20% | 7 | Jan 9, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $3.79 | +1,588.65% | 6 | Aug 15, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $216 → $184 | $12.93 | +1,323.05% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $2.10 | +900.00% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $7.22 | +94.04% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $0.39 | +3,999.41% | 2 | Dec 15, 2021 |
Geron
Jul 10, 2025
Reinstates: Sell
Price Target: $1
Current: $1.40
Upside: -28.57%
Rhythm Pharmaceuticals
Dec 5, 2024
Maintains: Buy
Price Target: $59 → $66
Current: $102.12
Upside: -35.37%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $32.21
Upside: -31.70%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $7.66
Upside: +95.82%
IDEAYA Biosciences
May 13, 2024
Maintains: Buy
Price Target: $53 → $46
Current: $27.16
Upside: +69.37%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $16 → $18
Current: $12.92
Upside: +39.32%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $3.78
Upside: +243.92%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $35.99
Upside: -22.20%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $3.79
Upside: +1,588.65%
RAPT Therapeutics
Mar 15, 2023
Maintains: Buy
Price Target: $216 → $184
Current: $12.93
Upside: +1,323.05%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $2.10
Upside: +900.00%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $7.22
Upside: +94.04%
Dec 15, 2021
Initiates: Neutral
Price Target: $16
Current: $0.39
Upside: +3,999.41%